Navigation Links
Pasta sauces recalled in cancer scare

European stores are removing thousands of jars of pasta sauces because they contain a cancer-causing dye normally used in gasoline and shoe polish.//

Sky News said consumers are being warned to avoid the affected brands, including Bertolli, as well as private-label sauces made for supermarket chains Sainsbury's and Safeway.

The alert follows the discovery of a red dye called Sudan 1 in chili powder used in the sauces. The dye -- classified as a carcinogen by the International Agency for Research on Cancer -- is normally used for industrial purposes in solvents, gasoline and shoe polish, but is banned in food.

The Safeway branded products are Red Pesto, Sun-dried Tomato and Balsamic Vinegar Stir-in Sauce, and Chargrilled Red Pepper and Vegetable Stir-in Sauce.

The Sainsbury's products are: Italian Tomato and Mascarpone Stir-in Sauce, Italian Sun-dried Tomato and Balsamic Vinegar Stir-in Sauce, Be Good to Yourself Mediterranean Vegetable Stir-in Sauce, and Italian Hot Mixed Peppers Pasta Sauce.

The only Bertolli sauces affected are 185g jars of Pesto Rosso.

Health officials told Sky News the amount of contaminated chili powder in the sauces is not believed to pose any immediate health risk.


'"/>




Page: 1

Related medicine news :

1. Salmonella Poisoned Frozen Pasta Hit Six
2. Hundreds of human tissue products been recalled
3. Vitamin B12 can help in detecting cancers
4. Want skin cancer? Please have a cigarette
5. New hope for cancer victims – will vaccine cure the deadly bug
6. Clintons new problem - Is the outgoing American president suffering from skin cancer?
7. Are cancer patients being taken for a ride?
8. Breast cancer treatment to be determined by gene test
9. Ductal lavage may detect early breast cancer
10. Beware of the oral patch! It could be cancer!!!
11. New drug helps boost cancer treatment
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Pasta sauces recalled cancer scare

(Date:9/4/2008)... may be shortchanging their golden years by tappin...iversity of Illinois expert who has studied the fe..., More than three of every four Americans trim th...iming benefits early, a choice many might forego i... consequences, law professor Richard L. Kaplan say...
(Date:9/4/2008)...ncology contract research organization, has publis...uanced Approach to Get Into the Clinic Faster.&quo...al research scientist with 35 years of experience,...mmonly viewed as straightforward investigations ru...rue integration with preclinical, regulatory and c...
(Date:9/4/2008)...NORWICH, England and ONGAR, Ireland,Sept. 4 /PRNe...ofield Media,Europe Ltd, announced on the 29th Aug... publication from Silverdog Publishing., Health a... the iconic,Health and Safety at Work Act 1974 and.... It has been relied upon by blue-chip corporates,...
(Date:9/4/2008)...-FirstCall/ -- ULURU Inc. (Amex:,ULU) today announ...Weisel,Partners Healthcare Conference at 3:15 p.m....out ULURU Inc.:, ULURU Inc. is an emerging specia...ent of a portfolio of wound management, plastic su...nd consumers improved clinical,outcomes through co...
Breaking Medicine News(10 mins):Health News:New guide explores making the most of Social Security 2Health News:New guide explores making the most of Social Security 3Health News:Oncology Clinical Research Scientist Recommends a Nuanced Preclinical Study Process to Speed Drug Development 2Health News:Oncology Clinical Research Scientist Recommends a Nuanced Preclinical Study Process to Speed Drug Development 3Health News:Schofield Publishing Enters the Newsletter Market 2
...seases caused by mutant prion proteins, such as ma...ted if normal prion proteins can be depleted, rese... human form of mad cow disease called variant Creu...e caused when prion protein in the brain becomes m...
...even rich countries will sign an agreement on Frid... poor countries, //the government of Italy, which ...sday. The new Advanced Market Commitments for Vac... the G7, is "aimed at saving millions of lives in ...
...vice may help people regain strength and normal us...ng to a University of California, Irvine study. ...proved ability to grasp and release objects after ...Assisting Robotic Device (HOWARD). Each patient ha...
...led Australians will soon enjoy better access to q...ebate created// at the AMA’s urging, AMA President...with an intellectual disability have some of the w...s, mostly because they can find it difficult to re...
Other Medicine News:Health News:Robotic Therapy Helps Restore Hand Use After Stroke 2Health News:Robotic Therapy Helps Restore Hand Use After Stroke 3
(Date:9/3/2008)...ldren Studied. Wrong,Conclusions Reached., NIXA, ...for Disease,Control and Prevention (CDC) study rel...R vaccine and autism. The National Autism Associat...he growing public concern over a,vaccine-autism co...esign,and methodology., For years, parents have c...
(Date:9/3/2008)...ically infected Hepatitis C,patients strongly conf...008, - Study is the first to show a statisticall...t of therapeutic Hepatitis C vaccination, - Data...ond generation, vaccine formulated with Intercell... activation, VIENNA, Austria, S...
(Date:9/3/2008)...-- Panacea Pharmaceuticals,Inc. today announced t...ng,antibodies against human aspartyl (asparaginyl)...er biomarker and therapeutic target. These antibod...chusetts Institute of,Technology (MIT) and Panacea...r development of human cancer diagnostics and ther...
(Date:9/3/2008)...o Launch Progress and Adlea ...e Call Today at 11:30 am ET, SOUTH SAN FRANCISCO,...,Inc. (Nasdaq: ANSV ) announced today that the c...mercial and late-stage product development to,acce...l pain management,company. The company also provid...
Breaking Medicine Technology:CDC Misses Target With Flawed MMR/Autism Study 2Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 2Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 3Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 4Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 2Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 3Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 4Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 2Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 3Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 4Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 5American Physicians Capital Inc Reports Third Quarter 2007 Results 4632 1American Physicians Capital Inc Reports Third Quarter 2007 Results 4632 2American Physicians Capital Inc Reports Third Quarter 2007 Results 4632 3American Physicians Capital Inc Reports Third Quarter 2007 Results 4632 4American Physicians Capital Inc Reports Third Quarter 2007 Results 4632 5American Physicians Capital Inc Reports Third Quarter 2007 Results 4632 6American Physicians Capital Inc Reports Third Quarter 2007 Results 4632 7American Physicians Capital Inc Reports Third Quarter 2007 Results 4632 8American Physicians Capital Inc Reports Third Quarter 2007 Results 4632 9American Physicians Capital Inc Reports Third Quarter 2007 Results 4632 10American Physicians Capital Inc Reports Third Quarter 2007 Results 4632 11American Physicians Capital Inc Reports Third Quarter 2007 Results 4632 12American Physicians Capital Inc Reports Third Quarter 2007 Results 4632 13AEterna Zentaris to Further Develop Three Follow up Multi targeted Cytotoxic Candidates to AEZS 112 as Potential Novel Cancer Treatment 1512 1AEterna Zentaris to Further Develop Three Follow up Multi targeted Cytotoxic Candidates to AEZS 112 as Potential Novel Cancer Treatment 1512 2AEterna Zentaris to Further Develop Three Follow up Multi targeted Cytotoxic Candidates to AEZS 112 as Potential Novel Cancer Treatment 1512 3AEterna Zentaris to Further Develop Three Follow up Multi targeted Cytotoxic Candidates to AEZS 112 as Potential Novel Cancer Treatment 1512 4BiPar Genomic Biomarker Data Demonstrate Overexpression of PARP 1 Gene in Multiple Cancer Types 668 1BiPar Genomic Biomarker Data Demonstrate Overexpression of PARP 1 Gene in Multiple Cancer Types 668 2Data Support use of SuperGens CLIMB Technology in Lead Development and Optimization 665 1Data Support use of SuperGens CLIMB Technology in Lead Development and Optimization 665 2Data Support use of SuperGens CLIMB Technology in Lead Development and Optimization 665 3
...y shows paroxetine produced no significant drug in... 2007 /PRNewswire/ -- After administration of,pali...ls of the,drug were not affected when given with a...ented today at the 160th Annual Meeting,of the Ame...tive,serotonin reuptake inhibitor (SSRI), is an an...
...AGA, Spain, May 23, 2007 /PRNewswire-FirstCall/ --...ntly completed animal,study, a DNA vaccine formula...vant and delivered by needle-free injection,yielde...unformulated DNA vaccine delivered by needle and s...n following injection of,unformulated vaccine yiel...
Other Medicine Technology:Blood Levels of Paliperidone Extended-Release Tablets are Not,Increased by Common Antidepressant 2Blood Levels of Paliperidone Extended-Release Tablets are Not,Increased by Common Antidepressant 3Blood Levels of Paliperidone Extended-Release Tablets are Not,Increased by Common Antidepressant 4Blood Levels of Paliperidone Extended-Release Tablets are Not,Increased by Common Antidepressant 5Blood Levels of Paliperidone Extended-Release Tablets are Not,Increased by Common Antidepressant 6Vical's Vaxfectin Adjuvant With Needle-free Delivery Enhances DNA,Vaccine Performance; Yields Antibody Responses Comparable to,Electroporation Without Tolerability Issues 2Vical's Vaxfectin Adjuvant With Needle-free Delivery Enhances DNA,Vaccine Performance; Yields Antibody Responses Comparable to,Electroporation Without Tolerability Issues 3Vical's Vaxfectin Adjuvant With Needle-free Delivery Enhances DNA,Vaccine Performance; Yields Antibody Responses Comparable to,Electroporation Without Tolerability Issues 4
The CRW system is the premier stereotactic system. The CRW system can be configured as a basic CT-only system, a CT/MR scanner-dependent system, or a high-level CT/MR scanner-independent system with
Table-mounted, retraction for radiolucent anterior spine procedures. Fully-adjustable for any approach and any patient. Combine with our radiolucent blade kit for optimal visibility.
Corlok Allografts are unique corticocancellous allografts comprised of an anterior cortical face and a unique Dovetail geometry permitting a precise interlocking fit with adjacent vertebrae. Corlok A
Solid cortical spacers with a natural anatomic fibular shape.
Medicine Products: